Paolo Becco
Ponderano, 13875, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
Journal: Journal of clinical medicine
Published: January 22, 2021
High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients.
Journal: ESMO open
Published: December 02, 2020
Melanoma Brain Metastases in the Era of Target Therapies: An Overview.
Journal: Cancers
Published: May 28, 2020
Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity.
Journal: The breast journal
Published: March 04, 2018
BRAF-inhibitors can exert control of disease in BRAF T599I mutated melanoma: a case report.
Journal: Melanoma research
Published: December 13, 2017
Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Published: September 28, 2016
TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.
Journal: Gynecologic oncology
Published: April 27, 2015
Showing 1-10 of 10
Last Updated: 09/26/2026